Protein A Resin Market Research Report: By Source (Recombinant, Natural), Matrix (Agarose-Based, Glass or Silica-Based, Organic Polymer-Based), Application (Antibody Purification, Immunoprecipitation), End User (Biotechnology and Pharmaceutical Industries, Academic Institutes and Research Laboratories) – Industry Size, Share, Trends and Forecast to 2030

The global protein A resin market generated an estimated revenue of $486.4 million in 2019, which is projected to reach $1,020.7 million by 2030, witnessing a CAGR of 7.0% during 2019–2030.

Among all regions, the APAC protein A resin market is expected to witness the fastest growth during the forecast period. Factors driving the growth of the market include surging burden of chronic diseases, rising investment and funding for protein-based research, and growing geriatric population.

Dynamics of Protein A Resin Market

In the protein A resin market, adoption of collaboration and partnership strategies by several players for the development of advanced next-generation protein A resins, and launch of new products are the key trends observed in the market. For instance, in June 2018, Repligen Corporation entered into an agreement with Purolite Corporation. As per the agreement, Repligen Corporation supplies its next-generation protein A ligand, NGL-Impact A, which is commercialized by Purolite Corporation by using its novel Praesto agarose jetting base bead technology.

Increasing investment and funding for protein-based research is the one of the primary factors driving the protein A resin market. Several public and private organizations are funding protein-based research programs to improve therapeutic approaches. For instance, the National Institute of Health (NIH), a medical research center based in the U.S., invests nearly $32.3 million annually in medical research by offering grants to projects and programs in the life sciences and medical fields. Besides, major key players in the biotechnology and pharmaceutical industries, such as Thermo Fisher Scientific Inc. and Merck & Co. Inc., are investing on R&D in the field of protein-based research for drug discovery and development.

According to the United Nations Population Fund, people aged 60 years or more account for 12.3% of the global population, which is projected to rise to almost 22% by 2050. Besides, the increasing prevalence of chronic diseases would raise the demand for novel therapeutic candidates for disease management. Since APAC accounts for around 60% of the global population, the region offers ample scope for the development of therapeutic agents derived from protein A resins.

Protein A Resin Market Segmentation Analysis

The recombinant source category is expected to grow at faster pace, with a CAGR of 7.5%, during 2019–2030. This can be ascribed to the fact that recombinant protein A resins are used in large quantity in the downstream processing of monoclonal antibody.

Agarose-based resins contain ionic and hydrophobic groups that interact with the compound of interest. In contrast, silica-based resins have silanol groups that require coatings before use in the size exclusion chromatography process. Hence, many antibody manufacturers prefer using agarose-based resins, thereby making these the largest shareholder in the matrix segment.

The antibody purification application category held larger market share in 2019. This is primarily due to high production and increasing demand for antibodies, particularly monoclonal antibody for therapeutic application.

Biotechnology and pharmaceutical industries, as an end-user category, in the protein A resin market are expected to witness faster growth during the forecast period. This can be imputed to the fact that these industries use a large amount of protein A resins in the production process of antibody.

Geographical Analysis of Protein A Resin Market

Globally, North America held the largest share, of 37.4%, in the protein A resin market in 2019. This is mainly attributed to the increasing demand for protein-based therapeutics for treating chronic conditions and rising number of the Food and Drug Administration (FDA) approved biopharmaceuticals in the region. Moreover, the presence of large-scale drug manufacturers, such as Gilead Sciences Inc. and Bayer AG, and the growing biopharma research industry are playing pivotal role in the growth of the market. The U.S. is expected to lead the North American market, owing to the increasing prevalence of chronic diseases, presence of established players, and rising number of protein-related research activities.

On the other hand, the APAC protein A resin market is projected to witness the fastest growth, with a CAGR of 7.8% during 2019–2030. This can be attributed to the increasing use of protein A resins in drug discovery, advancements in technologies, and rising number of life sciences research activities in the region. In 2019, Japan held the largest share in the APAC market, owing to the presence of well-established pharmaceutical industry and increasing R&D spending for the development of innovative and advanced drugs. Also, presence of pharmaceutical companies, such as Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., and Otsuka Holdings Co. Ltd., is supporting the growth of the market in the country.

Competitive Landscape of Protein A Resin Market

The protein A resin market is consolidated in nature, due to the presence of giant players, which are extensively involved in the development of protein A resins. These include GE Healthcare, Merck KGaA, Thermo Fisher Scientific Inc., Purolite Corporation, Tosoh Corporation, Novasep Holding SAS, and Repligen Corporation. Some of the other players operating in the market are Bio-Works Technologies AB, Amikozen Co. Ltd., Bio-Rad Laboratories Inc., Expedeon AG, GenScript Biotech Corporation, and Kaneka Corporation.

Recent Strategic Developments of Protein A Resin Market Players

In recent years, major players operating in the global protein A resin market have actively engaged in acquisition to gain a competitive edge. For instance, in February 2019, General Electric Company signed an agreement with Danaher Corporation to sell its biopharma business for $21.4 billion.

Market Size Breakdown by Segment

The Protein A Resin Market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.

Based on Source

• Recombinant
• Natural

Based on Matrix

• Agarose-Based
• Glass or Silica-Based
• Organic Polymer-Based

Based on Application

• Antibody Purification
• Immunoprecipitation

Based on End User

• Biotechnology and Pharmaceutical Industries
• Academic Institutes and Research Laboratories

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
• LATAM
  • Brazil
  • Mexico
• MEA
  • Saudi Arabia
  • South Africa

Key Questions Addressed in the Report

• What is the current scenario of the global protein A resin market?
• What are the historical size and the present size of the market segments and their future potential?
• What are the major catalysts for the market and their impact during the short, medium, and long terms?
• What are the evolving opportunities for the players in the market?
• Which are the key regions from the investment perspective?
• What are the product offerings by major players operating in the market?
• What are the key strategies being adopted by the major players to up their market shares?